PNU 109230

Drug Profile

PNU 109230

Latest Information Update: 16 Apr 2008

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Class Antibacterials
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gram-positive infections

Most Recent Events

  • 16 Apr 2008 Discontinued - Preclinical for Gram-positive infections in USA (unspecified route)
  • 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 20 Jan 1998 Preclinical development for Gram-positive infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top